ICMJE DISCLOSURE FORM

Date:	<u>November 25th, 2021</u>		
Your Name:	Satoru Iwasa		
Manuscript ³	Γitle: <u>NA</u>		
Manuscript i	number (if known):	DMR-21-89	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initial	planning of the work
1	All support for the present	x None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Daiichi Sankyo	research funding to my institution
	any entity (if not indicated	ONO	research funding to my institution
	in item #1 above).	Pfizer	research funding to my institution
		Astellas	research funding to my institution
		Taiho	research funding to my institution
		Eisai	research funding to my institution
		BMS	research funding to my institution
		Bayer	research funding to my institution
		Merck Biopharma	research funding to my institution
3	Royalties or licenses	x None	

4	Consulting fees	x None		
•				
5	Payment or honoraria for	ONO	Honoraria for lectures	
	lectures, presentations,	Chugai	Honoraria for lectures	
	speakers bureaus,	Lilly	Honoraria for lectures	
	manuscript writing or	Daiichi Sankyo	Honoraria for lectures	
	educational events	Taiho	Honoraria for lectures	
		BMS	Honoraria for lectures	
6	Payment for expert	x None		
	testimony			
	-			
7	Support for attending	x None		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	x None		
12	Receipt of equipment,	x None		
	materials, drugs, medical			
	writing, gifts or other			
42	services	N.		
13	Other financial or non-	x None		
	financial interests			

Please summarize the above conflict of interest in the following box:

None.			

Please place an "X" next to the following statement to indicate your agreement:		
x I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

ICMJE DISCLOSURE FORM

Date:	November 25 th , 20	<u>21</u>
Your Name:	Kei Muro	
Manuscript ¹	Γitle: <u>NA</u>	
Manuscript i	number (if known):	DMR-21-89

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Solasia Pharma Merck Serono Daiichi Sankyo Parexel International Pfizer MSD Amgen ONO Pharmaceutical Astellas Sanofi Taiho Eisai	research funding to my institution

		Novartis Pharma	research funding to my institution
3	Royalties or licenses	x None	research randing to my institution
J	Noyalties of ficerises		
4	Consulting fees	AstraZeneca	Consulting fees
		ONO Pharmaceutical	Consulting fees
		Amgen	Consulting fees
5	Payment or honoraria for	ONO Pharmaceutical	Honoraria for lectures
	lectures, presentations,	Chugai	Honoraria for lectures
	speakers bureaus,	Takeda, Taiho, Sanofi,	All honoraria for lectures
	manuscript writing or	Bristol-Myers Squibb, Eli	
	educational events	Lilly, Bayer	
6	Payment for expert	x None	
	testimony		
7	Support for attending	x None	
	meetings and/or travel		
8	Patents planned, issued or	x None	
	pending		
		2002	
9	Participation on a Data	ONO Pharmaceutical	Advisory Board
	Safety Monitoring Board or	MSD	Advisory Board
	Advisory Board	AstraZeneca	Advisory Board
		Daiichi Sankyo	Advisory Board
10	Londonahin on fishering a	Solasia Pharma	Advisory Board
10	Leadership or fiduciary role	x None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
11	Stock of Stock Options	XNOTIC	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	x None	
	financial interests		

Please summarize the above conflict of interest in the following box:

NI	
I None.	

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date:	ate: November 25 th , 2021		
Your Name:	Junichi Sakamot	to	
Manuscript ¹	Γitle: <u>NA</u>		
Manuscript i	number (if known):	DMR-21-89	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	x None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	x None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	x None	
4	Consulting fees	x None	
5		x None	

	Payment or honoraria for		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x None	
	testimony		
7	Support for attending meetings and/or travel	x None	
8	Patents planned, issued or pending	x None	
	pending		
9	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	x None	
12	Receipt of equipment,	x None	
	materials, drugs, medical		
	writing, gifts or other		
- 10	services		
13	Other financial or non-	x None	
	financial interests		
Ple	ase summarize the above co	nflict of interest in the fol	lowing box:
	None.		

Please place an "X" next to the following statement to indicate your agreement:

__x__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.